Who I am:

I'm a passionate and experienced executive leader and have been a key contributor and driver of global pharmaceutical R&D and Commercial teams across multiple therapeutic areas for 25+ years, delivering major business transformation and patient impact.

As Chief Commercial Data Science Officer for Johnson & Johnson Innovative Medicine, I lead a team that leverages the power of data, artificial intelligence and machine learning, real world evidence, digital health and precision medicine across the business to ensure our transformational medicines reach patients in need and to shape the future of the healthcare systems.

I am a founding co-chair of the cross-enterprise J&J AI Council, where I continue to play a pivotal role, and I also represent J&J Innovative Medicine on the J&J Data Management Council. I am also a member of the National Academy of Medicine Leadership Consortium's Digital Health Action Collaborative Taskforce on Large Language Models/Generative AI in Health and Medicine, as well as its Taskforce on Digital & Data Architecture in Health and Medicine.

Prior to my current role, I held several leadership positions of increasing responsibility at Johnson & Johnson, including playing pivotal roles in clinical development efforts for INVOKANA® and XARELTO® and serving as Vice President, Real-World Evidence for the North America pharmaceuticals business and Global Head of R&D Strategy for the Innovative Medicine portfolio.

Prior to joining J&J in 2005, I held roles in experimental medicine and clinical pharmacology at AstraZeneca in Sweden and the U.S. I have authored more than 80 scientific abstracts and publications and am an internationally renowned speaker. I earned both my Bachelor of Science (B.Sc.) and Ph.D. from The University of British Columbia.